Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News and Views
Nature Genetics 41, 509–510 (1 May 2009) | doi:10.1038/ng0509-509
TMPRSS2-ERG and PTEN loss in prostate cancer
Abstract
Recommendations over screening for early diagnosis of prostate cancer have recently gained attention, with increasing concern that the introduction of routine prostate-specific antigen (PSA) blood testing has led to significant overtreatment of prostate cancer. This debate highlights the need to better understand the primary molecular determinants that drive prostate cancer.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
